Prima BioMed to Maintain NASDAQ Listing

Prima BioMed to Maintain NASDAQ Listing

ID: 518220

(firmenpresse) - SYDNEY, AUSTRALIA -- (Marketwired) -- 01/18/17 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) the "Company" has received notification from the Listing Qualifications Department of the NASDAQ Stock Market indicating that the Company's American Depositary Shares have maintained a closing bid price of US$1.00 per share or greater for 10 consecutive business days from 28 December 2016 to 11 January 2017. Accordingly, the Company has regained compliance with NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule") and the Company's American Depositary Shares will remain listed on the NASDAQ Global Market.



Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit .



Mr. Matthew Beck
The Trout Group LLC
+1 (646) 378-2933


Mr. Matthew Gregorowski
Citadel-MAGNUS
+61 2 8234 0100




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Theratechnologies Inc.: Ibalizumab 24-Week Pivotal Phase III Study Results Accepted as a Late Breaker Will Be Presented at CROI 2017 Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer
Bereitgestellt von Benutzer: Marketwired
Datum: 18.01.2017 - 07:02 Uhr
Sprache: Deutsch
News-ID 518220
Anzahl Zeichen: 0

contact information:
Town:

SYDNEY, AUSTRALIA



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 272 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Prima BioMed to Maintain NASDAQ Listing"
steht unter der journalistisch-redaktionellen Verantwortung von

PRIMA BIOMED LTD (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

USA Patent Grants for IMP321 in Cancer ...

SYDNEY, AUSTRALIA -- (Marketwired) -- 02/28/17 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces the granting of patent number 9,579,382 entitled "Use of Recombinant LAG-3 or the Derivatives th ...

First Half 2017 Operational Update ...

SYDNEY, AUSTRALIA -- (Marketwired) -- 02/24/17 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)Positive recruitment rates for TACTI-mel and AIPAC clinical trialsOperational cash reach extended to first quarter 2018Prima BioMed Ltd would like to update ...

Alle Meldungen von PRIMA BIOMED LTD



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z